

Active Ingredient	Product Name / Strengt	Pharmaceutical Form	Therapeutic Area (Indication)	Target Time (DOSSIER AVAILABILITY)
Macitentan*	10 mg	Film coated tablet	Pulmonary arterial hypertension	AVAILABLE
Ivermectin*	1%	Topical cream	Acne rosacea	Q1.2023
Azelastine + Fluticasone *	125 mcg + 50 mcg	Nasal spray	Allergic rhinitis	Q2.2023
Azelastine*	0.14%	Nasal spray	Allergic rhinitis	Q2.2023
Lisdexamfetamine	10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg	Capsules	Attention defidic / Hyperactivity disorder	Q2.2024
Apixaban	2.5 mg, 5 mg	Film coated tablet	Anti-coagulant	Q3.2023
Apremilast	10 mg, 20 mg, 30 mg	Film coated tablet	Psoriasis/Behçet's Disease	Q3.2023
Edoxaban*	30 mg, 60 mg	Film coated tablet	Anti-coagulant	Q4.2023
Obethicolic Acid*	5 mg, 10 mg	Film coated tablet	Primary biliary cirrhosis	Q4.2023
Perampanel	2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg	Film coated tablet	Anti epileptic	Q1.2024
Tadalafil + Macitentan	40 mg + 10 mg	Film coated tablet	Pulmonary arterial hypertension	Q1.2024
Tapendatol	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg	Film coated tablet	Opioid	Q1.2025
Tenofovir Alafenamide + Emtricitabine	200 mg+ 25 mg	Film coated tablet	HIV	Q2.2024
Tenofovir Aleanamide	25 mg	Film coated tablet	Hepatitis B	Q2.2024
Empagliflozin	10 mg, 25 mg	Film coated tablet	Type 2 diabetes	Q3.2023
Riociguat*	0,5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg	Film coated tablet	Pulmonary arterial hypertension	Q3.2023
Pirfenidone	267 mg, 801 mg	Film coated tablet	Idiopathic pulmonary fibrosis	Q3.2024
Dolutegravir	10 mg, 25 mg, 50 mg	Film coated tablet	HIV	Q4.2023
Empagliflozin+Metformin	5 mg + 1000 mg, 12.5 mg + 1000 mg	Film coated tablet	Type 2 diabetes	Q4.2023
Dolutegravir+Lamivudin	50 mg + 300 mg	Film coated tablet	HIV	Q4.2025